Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Menu

Atea Pharmaceuticals Inc (AVIR)

Atea Pharmaceuticals Inc (AVIR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Atea Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update GlobeNewswire - Mon May 12, 3:11PM CDT

AVIR : 3.21 (+0.94%)
Atea Pharmaceuticals Announces Full Results from Phase 2 Study of Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus (HCV) Presented at EASL Congress 2025 GlobeNewswire - Wed May 7, 6:00AM CDT

AVIR : 3.21 (+0.94%)
Plus500
Plus500 Makes Futures Trading Truly Accessible: Low Margins and Up to $200 in a Commission-Free Bonus! Sponsored by Plus500

Trade the most popular US futures of 2025: Agricultural Commodities, Indices, Crypto, Metals, Forex, and more! Join over 30 million people worldwide who trust Plus500. Start trading today with a deposit as low as $100!

Atea Pharmaceuticals to Host Virtual HCV KOL Panel on May 14, 2025 GlobeNewswire - Thu May 1, 6:00AM CDT

AVIR : 3.21 (+0.94%)
Atea Pharmaceuticals to Present New Data Showcasing Potential Best-in-Class Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2025 GlobeNewswire - Wed Apr 23, 6:00AM CDT

AVIR : 3.21 (+0.94%)
Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program GlobeNewswire - Thu Apr 17, 6:00AM CDT

AVIR : 3.21 (+0.94%)
COYA : 5.88 (unch)
Atea Pharmaceuticals Announces Dosing of First Patient in C-BEYOND, Phase 3 Study Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus GlobeNewswire - Wed Apr 9, 6:00AM CDT

AVIR : 3.21 (+0.94%)
Atea Pharmaceuticals Highlights Actions Underway to Enhance Shareholder Value GlobeNewswire - Wed Mar 26, 12:58PM CDT

AVIR : 3.21 (+0.94%)
Atea Pharmaceuticals Issues Statement Regarding Director Nominations GlobeNewswire - Fri Mar 21, 4:54PM CDT

AVIR : 3.21 (+0.94%)
Atea Pharmaceuticals Announces Presentation of Bemnifosbuvir Preclinical Data at the 38th International Conference on Antiviral Research (ICAR) 2025 GlobeNewswire - Wed Mar 19, 6:00AM CDT

AVIR : 3.21 (+0.94%)

Barchart Exclusives

Stock Index Futures Tread Water as Investors Await Outcome of U.S.-China Trade Talks Barchart - 47 minutes ago
June S&P 500 E-Mini futures (ESM25) are up +0.03%, and June Nasdaq 100 E-Mini futures (NQM25) are up +0.05% this morning as trade talks between the U.S. and China extended into a second day, with investors cautiously awaiting the outcome. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot
OSZAR »